Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Pre-Operative Durvalumab in Early Small Triple Negative Breast Cancer (POP-Durva)
2024-512082-14-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab in triple-negative breast cancer (TNBC), sponsored by Gustave Roussy. Started Apr 2024; status: completed.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512082-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512082-14-00.